Bolt Biotherapeutics, Inc.
For the period ended Dec 31, 2025. Filed Mar 12, 2026.
View on SEC.govAbout this filing
A company's yearly report to the SEC, with audited financial statements. It is the fullest account a company gives of its business, its finances and the risks it sees.
FY2025 · Filed Mar 12, 2026
BOLT$6.30-2.0%Stored close · as of Nov 10, 2026
Extracted filing text, with the paragraph anchors used by the comparison.
See the whole filing, with its images and exhibitsContents
Item 8. Consolidated Statements of Cash Flows
CONSOLIDATED STATE MENTS OF CASH FLOWS
(in thousands)
| Years Ended December 31, | ||
|---|---|---|
| 2025 | 2024 | |
| CASH FLOWS FROM OPERATING ACTIVITIES: | ||
| Net loss | $(33,376) | $(63,118) |
| Adjustments to reconcile net loss to net cash used in operating activities: | ||
| Depreciation and amortization | 1,291 | 1,781 |
| Stock-based compensation expense | 2,782 | 7,407 |
| Accretion of discount on marketable securities | (670) | (2,615) |
| Gain on sale of fixed assets | (288) | (70) |
| Asset impairment | — | 1,469 |
| Non-cash lease expense | 2,526 | 2,297 |
| Changes in operating assets and liabilities: | ||
| Prepaid expenses and other assets | 76 | 2,571 |
| Accounts payable and accrued expenses | (5,430) | (4,883) |
| Operating lease liabilities, net | (2,251) | (1,412) |
| Deferred revenue | (4,642) | (4,673) |
| Other long-term liabilities | 132 | (43) |
| Net cash used in operating activities | (39,850) | (61,289) |
| CASH FLOWS FROM INVESTING ACTIVITIES: | ||
| Purchase of property and equipment | (72) | (41) |
| Proceeds from sales of property and equipment | 963 | 148 |
| Purchases of marketable securities | (29,016) | (88,855) |
| Maturities of marketable securities | 72,427 | 146,324 |
| Net cash provided by investing activities | 44,302 | 57,576 |
| CASH FLOWS FROM FINANCING ACTIVITIES: | ||
| Proceeds from issuance of common stock | 19 | 108 |
| Net cash provided by financing activities | 19 | 108 |
| NET INCREASE (DECREASE) IN CASH | 4,471 | (3,605) |
| Cash, cash equivalents and restricted cash at beginning of year | 8,970 | 12,575 |
| Cash, cash equivalents and restricted cash at end of period | $13,441 | $8,970 |
| Reconciliation of cash, cash equivalents and restricted cash: | ||
| Cash and cash equivalents | $11,703 | $7,205 |
| Restricted cash | 1,738 | 1,765 |
| Total cash, cash equivalents and restricted cash | $13,441 | $8,970 |
| Supplemental schedule of non-cash investing and financing activities: | ||
| Right of use assets obtained in exchange for operating lease obligations | $— | $6,402 |
The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.